Showing 1 - 5 results of 5 for search 'Erica Bonazzina', query time: 0.02s Refine Results
  1. 1
    The Evolutionary Landscape of Treatment for <i>BRAF<sup>V600E</sup></i> Mutant Metastatic Colorectal Cancer

    The Evolutionary Landscape of Treatment for <i>BRAF<sup>V600E</sup></i> Mutant Metastatic Colorectal Cancer by Gianluca Mauri, Erica Bonazzina, Alessio Amatu, Federica Tosi, Katia Bencardino, Viviana Gori, Daniela Massihnia, Tiziana Cipani, Francesco Spina, Silvia Ghezzi, Salvatore Siena, Andrea Sartore-Bianchi

    Published 2021-01-01
    Get full text
    Article
  2. 2
    Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study

    Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study by Alessio Amatu, Gianluca Mauri, Federica Tosi, Katia Bencardino, Erica Bonazzina, Viviana Gori, Lorenzo Ruggieri, Sabrina Arena, Alberto Bardelli, Silvia Marsoni, Salvatore Siena, Andrea Sartore-Bianchi

    Published 2022-02-01
    Get full text
    Article
  3. 3
    Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

    Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer by Gianluca Mauri, Gianluca Mauri, Gianluca Mauri, Giorgio Patelli, Giorgio Patelli, Viviana Gori, Viviana Gori, Calogero Lauricella, Benedetta Mussolin, Alessio Amatu, Katia Bencardino, Federica Tosi, Erica Bonazzina, Emanuela Bonoldi, Alberto Bardelli, Alberto Bardelli, Salvatore Siena, Salvatore Siena, Andrea Sartore-Bianchi, Andrea Sartore-Bianchi

    Published 2023-03-01
    Get full text
    Article
  4. 4
    Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

    Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer by Gianluca Mauri, Gianluca Mauri, Gianluca Mauri, Giorgio Patelli, Giorgio Patelli, Viviana Gori, Viviana Gori, Calogero Lauricella, Benedetta Mussolin, Alessio Amatu, Katia Bencardino, Federica Tosi, Erica Bonazzina, Emanuela Bonoldi, Alberto Bardelli, Alberto Bardelli, Salvatore Siena, Salvatore Siena, Andrea Sartore-Bianchi, Andrea Sartore-Bianchi

    Published 2022-11-01
    Get full text
    Article
  5. 5
    High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib

    High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib by Alessio Amatu, Marta Schirripa, Federica Tosi, Sara Lonardi, Katia Bencardino, Erica Bonazzina, Laura Palmeri, Damiano Alfio Patanè, Elio Gregory Pizzutilo, Benedetta Mussolin, Francesca Bergamo, Giulia Alberti, Giulia Alberti, Rossana Intini, Letizia Procaccio, Letizia Procaccio, Marco Arese, Marco Arese, Silvia Marsoni, Silvia Marsoni, Michele Nichelatti, Vittorina Zagonel, Salvatore Siena, Salvatore Siena, Alberto Bardelli, Alberto Bardelli, Fotios Loupakis, Federica Di Nicolantonio, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Andrea Sartore-Bianchi, Ludovic Barault, Ludovic Barault

    Published 2019-07-01
    Get full text
    Article

Search Tools: